In 2023, the sales of Genito Urinary System and Sex Hormones in Canada stood at 1.27 billion US dollars in PPP terms. Forecasted data from 2024 to 2028 shows a consistent value of 1.27 billion annually, indicating a plateau in growth during this period. The year-on-year variation is 0%, suggesting no expansion or contraction in market size over these years. The compound annual growth rate (CAGR) over the last five years remains at 0%, further affirming stagnation.

Future trends to watch for:

Potential market shifts driven by new medical advancements or emerging competitors.
Changes in regulatory policies that could impact drug pricing or market access.
Demographic trends influencing demand for related healthcare products and services.